Literature DB >> 17655934

Allosteric properties of G protein-coupled receptor oligomers.

Jean-Yves Springael1, Eneko Urizar, Sabine Costagliola, Gilbert Vassart, Marc Parmentier.   

Abstract

Allosteric regulation of ligand binding is a well-established mechanism regulating the function of G protein-coupled receptors (GPCR). Allosteric modulators have been considered so far as molecules binding to an allosteric site, distinct from that of the reference ligand (orthosteric site), and able to modulate the binding affinity at the orthosteric site and/or the signaling properties resulting from orthosteric site occupancy. Given that most GPCR are known to form dimers or higher order oligomers, we explored whether allosteric interactions could also occur between protomers within oligomeric arrays, thereby influencing binding and signaling receptor properties. Two main conclusions emerged from such studies. First, allosteric modulators can affect one receptor by binding to another receptor within a dimeric or oligomeric complex. Second, allosteric modulators might act on a given receptor by targeting the "orthosteric site" in another receptor of the complex. Allosteric regulation within di(oligo)mers thus implies that the pharmacological properties of a given receptor subtype can be influenced by the array of dimerization partners coexpressed in each particular cell type. Ligands could thus act as agonists or antagonists on 1 receptor, while modulating allosterically the function of a variety of other receptors to which they do not bind directly. Allosteric regulation across GPCR oligomeric interfaces is expected to greatly influence the practice of pharmacology. It will likely affect the design of drug discovery programs, which rely mostly on the overexpression of the receptor of interest in a cell line, thereby focusing on homo-oligomers and ignoring the potential effects of other partners.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655934     DOI: 10.1016/j.pharmthera.2007.06.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  41 in total

1.  Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation.

Authors:  Carine Monnier; Haijun Tu; Emmanuel Bourrier; Claire Vol; Laurent Lamarque; Eric Trinquet; Jean-Philippe Pin; Philippe Rondard
Journal:  EMBO J       Date:  2010-11-09       Impact factor: 11.598

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

4.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 5.  On the fitting of binding data when receptor dimerization is suspected.

Authors:  J Giraldo
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 6.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

7.  Bioluminescence resonance energy transfer studies reveal constitutive dimerization of the human lutropin receptor and a lack of correlation between receptor activation and the propensity for dimerization.

Authors:  Rongbin Guan; Xiuyan Feng; Xueqing Wu; Meilin Zhang; Xuesen Zhang; Terence E Hébert; Deborah L Segaloff
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

8.  Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4.

Authors:  Fabien M Décaillot; Raphael Rozenfeld; Achla Gupta; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-03       Impact factor: 11.205

9.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

10.  Direct interaction of GABAB receptors with M2 muscarinic receptors enhances muscarinic signaling.

Authors:  Stephanie B Boyer; Sinead M Clancy; Miho Terunuma; Raquel Revilla-Sanchez; Steven M Thomas; Stephen J Moss; Paul A Slesinger
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.